Bio-Rad Laboratories (BIO.B) vs Insulet (PODD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Bio-Rad Laboratories (BIO.B) has outperformed Insulet (PODD) over the past year, gaining 28.2% versus a loss of 57.8%. Over five years, BIO.B leads with a -50.5% price change compared with -55.0% for PODD. Bio-Rad Laboratories is the larger company by market cap ($9.76 billion vs $9.38 billion), about 1.0 times the size, while Insulet is growing revenue faster (+30.7% vs +0.7%).
On valuation, Insulet trades at a lower trailing P/E (25.3x vs 46.3x for Bio-Rad Laboratories). Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus 9.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | PODD |
|---|---|---|
| Share price | $365.08 | $135.28 |
| Market cap | $9.76B | $9.38B |
| 1-day change | 0.00% | +0.60% |
| YTD return | +17.50% | -52.41% |
| 1-year return | +28.15% | -57.78% |
| 5-year return | -50.54% | -54.98% |
| P/E ratio (TTM) | 46.27 | 25.33 |
| Forward P/E | — | 17.51 |
| EPS (TTM) | $7.89 | $5.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | $2.71B |
| Revenue growth (YoY) | +0.65% | +30.73% |
| Net income (latest FY) | $759.90M | $247.10M |
| Gross margin | 51.87% | 71.63% |
| Operating margin | 1.83% | 17.50% |
| Net margin | 29.42% | 9.12% |
| 52-week high | $365.08 | $354.88 |
| 52-week low | $244.54 | $126.40 |
| Distance from 52-week high | 0.00% | -61.88% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +26.37% |
| Average volume | 4 | 1.69M |
| Shares outstanding | 5.06M | 69.35M |
| Employees | 7,450 | 5,400 |
| Sector | Healthcare | Health Care |
| Industry | Medical Devices | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIO.B has outperformed PODD by 85.9 percentage points over the past year.
- Bio-Rad Laboratories trades at a higher earnings multiple (46.3x vs 25.3x trailing P/E).
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus 9.1 cents for Insulet.
- Insulet grew revenue faster in its latest fiscal year (+30.73% vs +0.65%).
- The two companies sit in different sectors: Bio-Rad Laboratories in Healthcare and Insulet in Health Care.
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
BIO.B vs PODD FAQ
Which is bigger, Bio-Rad Laboratories or Insulet?
Bio-Rad Laboratories (BIO.B) is larger, with a market capitalization of $9.76B compared with $9.38B for Insulet (PODD).
Which stock has performed better over the past year, BIO.B or PODD?
BIO.B returned +28.15% over the past 12 months, compared with -57.78% for PODD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIO.B or PODD?
PODD has the lower trailing P/E at 25.3, versus 46.3 for BIO.B. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Bio-Rad Laboratories and Insulet in the same industry?
No. Bio-Rad Laboratories is in the Healthcare sector, while Insulet is in Health Care.